Compare Incyte Corporation (INCY) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ProShares UltraPro S&P500 — how do they compare? Incyte Corporation trades at $120.95 (market cap $24.54B), while ProShares UltraPro S&P500 trades at $154.9. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | UPRO | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $155.10 |
52-Week Low | $81.61 | $89.29 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
UPRO trades at $154.38, down 0.39% on the day, while maintaining a bullish technical outlook with strong moving average signals. The leveraged ETF tracking the S&P 500 faces mixed sentiment as oscillators show neutral readings amid record market highs. Recent institutional activity includes Bay Colony Advisors establishing a new position, indicating professional interest despite valuation concerns in the broader market.
The ETF's performance remains tied to S&P 500 momentum, with technical strength supporting near-term upside potential. However, elevated RSI levels and market-wide valuation concerns present headwinds. The absence of traditional fundamental metrics for this leveraged product emphasizes its tactical rather than long-term investment nature.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
